STOCKHOLM, April 7, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, today announced a significant milestone ...

Net sales were TSEK 12,475 (8,598), +45%, cleared for currency effects +57%. The loss after tax was TSEK 25,300 (21,677). The loss per share was SEK 0.06 (0.10). The cash flow from current operations ...

STOCKHOLM, Nov. 12, 2019 /PRNewswire/ -- SciBase a leading developer of electrical impedance spectroscopy systems in dermatology, announced today that The Kimberly and Eric J. Waldman Department of ...

Castle Biosciences (NASDAQ:CSTL) has partnered with SciBase Holding AB to develop a diagnostic test aimed at forecasting flare-ups in individuals suffering from atopic dermatitis. The agreement will ...

STOCKHOLM, March 10, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, is pleased to announce the publication of ...

STOCKHOLM, Jan. 9, 2026 /PRNewswire/ -- The Board of Directors of SciBase Holding AB (publ) ("SciBase" or the "Company") publishes information documents in connection with the rights issue of shares ...

STOCKHOLM--(BUSINESS WIRE)--SciBase (STO:SCIB), who in June of this year took over the manufacturing of their single-use electrode from Ginolis, has appointed Anna Danström as Supply Chain & ...

STOCKHOLM--(BUSINESS WIRE)--Regulatory News: SciBase (STO:SCIB) The interest in and acceptance of SciBase’s method for early detection of malignant melanoma is increasing, which is demonstrated by the ...

Higher Sensitivity: EIS captured early, and subtle structural changes not detected by TEWL measurement, highlighting its value for quantifying skin barrier impairment and complementing established ...

Oct 1 -Dec 31 Jan 1 -Dec 31 THE GROUP 2025 2024* 2025 2024* Net sales, SEK ths 12 475 8 598 40 461 29 705 Gross margin, % 63,0 % 68,5 % 67,0 % 71,0 % Equity/Asset ratio, % 12,8 % 59,4 % 12,8 % 59,4 % ...